Research Funded by Box Rallies

Engineering childhood cancer for precision medicine

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

Finding new treatment targets for advanced melanoma

Finding new ways to treat liver cancer

Functional characterisation of the putative tumour suppressor gene MCC in colorectal cancer

Gene modified T cells expressing a chimeric antigen receptor for a kappa light chain antigen to treat multiple myeloma

HCC Outcomes mitigation and disease Prevention through Clinical Partnerships (HOPE)

Harnessing androgen-mediated viral mimicry to improve immunotherapy in prostate cancer

Ibudilast as a treatment for chemotherapy-induced peripheral neuropathies and cognitive impairments

Identification and targeting of a new subtype of estrogen receptor breast positive breast cancer

Identifying the drivers of stomach cancer to find more effective treatments

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

Improving the health and well-being of women cancer survivors

Investigating a gene that helps neuroblastomas grow blood vessels and spread throughout the body

Investigating why a new brain cancer drug works in some patients but not others

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

Linking gut bacteria to the development of early onset colorectal cancer using multi-omic profiling

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target